论文部分内容阅读
[目的]评价卡培他滨联合奥沙利铂治疗老年晚期胃癌的临床疗效和毒副反应。[方法]32例老年胃癌患者,予以卡培他滨2000mg/m2,d1~14口服,奥沙利铂100mg/m2,d1,每21d为1个周期,完成2个周期后评价疗效,并观察毒副反应。[结果]28例可评价,总有效率42.9%,中位疾病进展时间6.1个月,1年生存率43.4%。毒副反应以粒细胞减少、乏力、贫血为主,Ⅲ~Ⅳ度毒副反应少见。[结论]卡培他滨联合奥沙利铂治疗老年晚期胃癌显示了较好的疗效,患者耐受性较好。
[Objective] To evaluate the clinical efficacy and toxicity of capecitabine combined with oxaliplatin in the treatment of elderly patients with advanced gastric cancer. [Method] 32 elderly patients with gastric cancer were treated with capecitabine 2000mg / m2, d1 ~ 14 orally, oxaliplatin 100mg / m2, d1 every 21d for 1 cycle. After 2 cycles, the curative effect was evaluated and observed Toxic reaction. [Results] 28 cases were evaluable, the total effective rate was 42.9%, the median disease progression time was 6.1 months, and the 1-year survival rate was 43.4%. Toxicity to neutropenia, fatigue, anemia, Ⅲ ~ Ⅳ degrees of rare side effects. [Conclusion] Capecitabine combined with oxaliplatin in elderly patients with advanced gastric cancer shows good curative effect and patients are well tolerated.